Literature DB >> 31632823

Pathologic complete response is not equivalent to cure in esophageal cancer.

Rebecca Carr1, Daniela Molena1.   

Abstract

Entities:  

Year:  2019        PMID： 31632823      PMCID： PMC6783786          DOI： 10.21037/jtd.2019.08.110

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

1.  Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer.

Authors:  Lisa A Kachnic; Kathryn Winter; Todd Wasserman; David Kelsen; Robert Ginsberg; Thomas M Pisansky; James Martenson; Ritsuko Komaki; Gordon Okawara; Seth A Rosenthal; Christopher G Willett; Bruce D Minsky
Journal:  Gastrointest Cancer Res       Date:  2011-03

2.  Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.

Authors:  Shao-Lun Lu; Feng-Ming Hsu; Chiao-Ling Tsai; Jang-Ming Lee; Pei-Ming Huang; Chih-Hung Hsu; Chia-Chi Lin; Yih-Leong Chang; Min-Shu Hsieh; Jason Chia-Hsien Cheng
Journal:  Eur J Surg Oncol       Date:  2019-03-19       Impact factor: 4.424

Review 3.  The relevance and implications of signet-ring cell adenocarcinoma of the oesophagus.

Authors:  Christopher William Bleaney; Mickhaiel Barrow; Stephen Hayes; Yeng Ang
Journal:  J Clin Pathol       Date:  2017-12-06       Impact factor: 3.411

4.  Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.

Authors:  Jing Jin; Zhongxing Liao; Zhen Zhang; Jaffer Ajani; Stephen Swisher; Joe Y Chang; Melanda Jeter; Thomas Guerrero; Craig W Stevens; Ara Vaporciyan; Joe Putnam; Garret Walsh; Roy Smythe; Jack Roth; James Yao; Pamela Allen; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-10-01       Impact factor: 7.038

5.  Prognostic implications of signet ring cell histology in esophageal adenocarcinoma.

Authors:  Sai Yendamuri; Miriam Huang; Usha Malhotra; Graham W Warren; Paul N Bogner; Chukwumere E Nwogu; Adrienne Groman; Todd L Demmy
Journal:  Cancer       Date:  2013-05-29       Impact factor: 6.860

6.  Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation.

Authors:  Guillaume Piessen; Mathieu Messager; Emmanuelle Leteurtre; Triboulet Jean-Pierre; Christophe Mariette
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

7.  Adenocarcinoma of the esophagus with signet ring cell features portends a poor prognosis.

Authors:  Jonathan M Enlow; Chadrick E Denlinger; Martha R Stroud; Jonathan S Ralston; Carolyn E Reed
Journal:  Ann Thorac Surg       Date:  2013-08-27       Impact factor: 4.330

8.  Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience.

Authors:  Mariela Blum Murphy; Lianchum Xiao; Viren R Patel; Dipen M Maru; Arlene M Correa; Fatemeh G Amlashi; Zhongxing Liao; Ritsuko Komaki; Steven H Lin; Heath D Skinner; Ara Vaporciyan; Garrett L Walsh; Stephen G Swisher; Boris Sepesi; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Wayne L Hofstetter; Jaffer A Ajani
Journal:  Cancer       Date:  2017-09-08       Impact factor: 6.860

9.  Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis.

Authors:  Steven Engel; Adam Awerbuch; Deukwoo Kwon; Omar Picado; Raphael Yechieli; Danny Yakoub; Lorraine Portelance
Journal:  J Gastrointest Oncol       Date:  2019-06

Review 10.  The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature.

Authors:  Dimitrios Schizas; Ioannis I Lazaridis; Demetrios Moris; Aikaterini Mastoraki; Lazaros-Dimitrios Lazaridis; Diamantis I Tsilimigras; Nikolaos Charalampakis; Theodore Liakakos
Journal:  World J Surg Oncol       Date:  2018-03-14       Impact factor: 2.754
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.